Side effects deserve greater emphasis at end of life

BMJ 2004; 330 doi: https://doi.org/10.1136/bmj.330.7481.43-a (Published 30 December 2004) Cite this as: BMJ 2004;330:43
  1. Adam Harper, acting consultant geriatrician (adamharper@doctors.org.uk),
  2. Jan Ritchie, registrar,
  3. Jeremy Rowland, senior house officer,
  4. Vladimir Malykh, honorary preregistration house officer
  1. Department of Medicine for Older People, Southampton General Hospital, Southampton SO16 6YD

    EDITOR—We agree with many of the points made by Stevenson et al on managing comorbidities at the end of life, particularly the emphasis on assessing the overall benefits of treatment kept in perspective through numbers needed to treat or absolute risk reduction, often much smaller …

    View Full Text

    Sign in

    Log in through your institution